Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients

Amryt Pharma Plc AMYT has presented long-term from the 2nd year open-label extension (OLE) of its Phase 3 OPTIMAL trial of Mycapssa (octreotide capsules in acromegaly.

  • The trial compared long-term safety and efficacy data of Mycapssa to placebo for maintenance of biochemical response in patients with acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone during adulthood.
  • The data demonstrated that 100% of evaluable patients who entered the 2nd year OLE phase of the study as responders - insulin-like growth factor 1 (IGF-1) within normal limits - maintained their long-term biochemical response at the end of the study.
  • Related: Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus.
  • IGF-1 levels were stably maintained within normal limits at the end of the OLE period.
  • Growth hormone (GH) levels also improved at the end of the OLE period.
  • The long-term safety profile of Mycapssa during the OLE was consistent with that observed in prior studies.
  • Price Action: AMYT shares are up 1.97% at $7.76 during the market session on the last check Wednesday.

Posted In: BriefsBiotechNewsHealth CareSmall CapGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.